We propose cell and gene therapy trial infrastructure that will focus on hereditary hematological and immunologic disorders and on anti-inflammatory lung disorders. This alpha stem cell clinic operation at UCSF…
Our project objective is to develop a sustainable infrastructure and become a Northern California hub for stem cell therapies, thus both reducing current patient burden and increasing access to this…
We propose a cellular trial operation at UCSF that will focus on childhood hereditary hematological and immunologic disorders and in anti-inflammatory lung cellular therapies. This alpha clinic operation at UCSF…
The UC Davis Alpha Clinic will provide pivotal resources to assist in the approval & conducting of stem cell/regenerative medicine clinical trials. A centralized space & personnel to administer the…
We propose a cellular trial operation at UCSF that will focus on childhood hereditary hematological and immunologic disorders and in anti-inflammatory lung cellular therapies. This alpha clinic operation at UCSF…
Therapeutic Candidate or Device SENTI-202 is an allogeneic off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cellular therapy targeting CD33 and/or FLT3 malignancies. Indication CD33 and/or FLT3 expressing hematologic malignancies,…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
